Manufacturing news briefs — stories you might have missed

Cyclopharm raises $20 million, seeks another $2 million Radiopharmaceutical imaging company Cyclopharm has successfully completed its institutional placement, raising $20 million before costs. The Placement attracted strong demand from both existing shareholders and from new institutional and sophisticated investors in Australia, Hong Kong, and the UK. A share purchase plan to raise up to $2.0…

Cyclopharm achieves streamlined reimbursement for Technegas in the US

Cyclopharm’s Technegas radiopharmaceutical imaging system has achieved a streamlined reimbursement approval process in the United States, boosting its prospects in what is the world’s largest market. The Sydney company has received a Coding Determination for Technegas from the Center for Medicare Medicaid Services (CMS), which means users will have a unique identifier which streamlines their…

Cyclopharm’s Technegas approved for US market in sales milestone

The US Food and Drug Administration has approved Cyclopharm’s lung imagining technology Technegas, opening up a US$180 million market that has the potential to quadruple the size of Cyclopharm’s existing Pulmonary Embolism (PE) market. Technegas is an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging in 64 countries…